Hansa Biopharma — September 2021
-
"Fireside chat" med CEO Sören Tulstrup and HCW analyst, Doug Tsao fra mandag d. September https://journey.ct.events/view/d8cfcd63-2a59-4466-92ad-5a4949c7c0e5
-
Link til MorganStanley webcast chat med CEO Søren Tulstrup og research analyst James Quigley, MorganStanley, UK https://morganstanley.webcasts.com/starthere.jsp?ei=1488480&tp_key=627eaeddc2
-
Erik Penser Bank fortsætter køb i Hansa, i dag købt 52060 - solgt 0. Nu kunne det være rart med lidt nyheder, så vi kunne få sat de amerikanske banker under pres.
-
Kurstriggere: 1- Første nyretransplation usa-studie. 2- Samarbejde med Argenx går i klinikken med første projekt. 3- PM om opstart study to investigate DSA rebound in patients treated with imlifidase prior to transplation (levende organdonation).
-
Kurstriggere: 4- Ny genterapi-aftale. 5. Nye Reimbursaftaler. 6- Sektorrotation til biotek.
-
Kurstriggere: 7- Ja så selvfølgelig den der bare ikke må ske, opkøb af hele butikken til emissionskurs Skr. 250 + 10-20%
-
Temadag EPB. Søren Ulstrups afsluttende bemærkning i interview/spørgsmål: We have the opportunity to build the next Alexion or Shire. ( Alexion overtaget af Astrazeneca for 39B $, Shire overtaget af Takeda for 62B $).
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind